http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021162308-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0eb77f2195d70c603a944e40beb9a5e9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2021-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca7f8db79274f9dc2689c19c866b9a85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cd7bf452b4e660e0e06262f38d4374c |
| publicationDate | 2021-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021162308-A1 |
| titleOfInvention | Analysis method for increasing susceptibility to sorafenib treatment in hepatocellular carcinoma |
| abstract | The present invention provides an analysis method for providing information needed for the diagnosis of hepatocellular carcinoma patients having susceptibility to sorafenib. It was discovered by the present invention that, when the expression levels of eight genes in tumor tissue of a hepatocellular carcinoma patient, i.e., CDH1, CHAD, EFNA2, FANCC, MAP2K1, MEN1, PBRM1, and PPARG genes, are combined and analyzed, a response (susceptibility) to sorafenib can be predicted with high accuracy. Thus, a combination of the genes can be effectively used as a biomarker for selecting hepatocellular carcinoma patients having susceptibility to sorafenib. |
| priorityDate | 2020-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.